Maci 3CM x 5CM implant sheets
Ended Awarded Last action
- Contract number
- SPE2DR26FSCB8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $63,176
Award facts
- Contract value 100% obligated
- $63,175.92 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $63,175.92 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for MACI 3cm x 5cm implant sheets. The delivery order, issued on December 17, 2025, with an ultimate completion date of January 9, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. MACI (matrix-applied characterization implants) are specialized surgical products used in orthopedic and tissue repair applications, consistent with DMS Pharmaceutical Group's extensive portfolio of specialty pharmaceuticals and medical consumables supplied to Department of Defense healthcare facilities.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR and valued at $499.9 billion through December 31, 2036. The PPV-G GEN V program is a $30.3 billion Department of Defense acquisition strategy that establishes multiple regional prime vendor contractors to supply comprehensive pharmaceutical products and medical consumables to military healthcare facilities worldwide. As a critical supplier within this framework, DMS Pharmaceutical Group leverages its established performance record and small business status to fulfill the diverse and specialized pharmaceutical requirements of the federal military medical system across multiple therapeutic categories.
Quick answers
Who was awarded contract SPE2DR26FSCB8?
SPE2DR26FSCB8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 17, 2025.
How much is contract SPE2DR26FSCB8 worth?
The government has obligated $63,176 on SPE2DR26FSCB8.
Is contract SPE2DR26FSCB8 an order under another contract?
Yes. SPE2DR26FSCB8 is a delivery order under SPE2DR25D9316, an indefinite delivery contract.
Was contract SPE2DR26FSCB8 competed?
The extent of competition for SPE2DR26FSCB8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award